EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Microbiome-directed therapies in oncology: from animal models to clinical implementation

Karolina Skonieczna-Żydecka, Maria Marlicz, Mariusz Kaczmarczyk, Igor Łoniewski, Patrycja Boluk, Natalia Ekstedt-Biskot, Krzysztof Kutrzuba, Wojciech Marlicz

Best Practice & Research Clinical Gastroenterology · 2026-08 · 83 · 102148

DOI: 10.1016/j.bpg.2026.102148 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2026-08. Verfasst von Karolina Skonieczna-Żydecka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemical Science, Pomeranian Medical University in Szczecin, Broniewskiego 24, Szczecin, 71-460, Poland. Hauptthemen laut MEDLINE: Probiotics, Neoplasms, Gastrointestinal Microbiome, Dysbiosis. Die Arbeit nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiota is increasingly recognized as a key regulator of cancer development, antitumor immunity, treatment response, and therapy-related toxicity. Microbial dysbiosis contributes to chronic inflammation, impaired intestinal barrier function, and immune dysregulation, thereby influencing oncological outcomes. This review summarizes current evidence on probiotics and microbiome-directed interventions in oncology, from mechanistic studies to emerging clinical applications. We discuss interactions among the gut microbiota, microbial metabolites, the immune system, and the tumor microenvironment, highlighting pathways that may affect carcinogenesis, treatment efficacy, and adverse events. Particular attention is given to the role of probiotics in maintaining barrier integrity, modulating immune responses, and reducing gastrointestinal toxicity. While preclinical studies suggest that selected probiotics can enhance antitumor immunity and treatment responses, clinical evidence primarily supports benefits in reducing gastrointestinal complications and improving quality of life. Microbiome modulation represents a promising adjunctive strategy in precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsNeoplasmsGastrointestinal MicrobiomeDysbiosisHumansAnimalsTumor MicroenvironmentDisease Models, AnimalIntestinal Barrier Function

Stichwörter der Autor:innen

CancerImmunotherapyMicrobial therapeuticsMicrobiome modulationPrecision oncologyTreatment-related toxicity

Autor:innen und Institutionen

  • Department of Biochemical Science, Pomeranian Medical University in Szczecin, Broniewskiego 24, Szczecin, 71-460, Poland.
  • Department of Gastroenterology, Pomeranian Medical University in Szczecin, Unii Lubelskiej 1, Szczecin, 71-252, Poland. Electronic address: marlicz@hotmail.com.

Zitieren

APA

Skonieczna-Żydecka, K., Marlicz, M., Kaczmarczyk, M., Łoniewski, I., Boluk, P., Ekstedt-Biskot, N., Kutrzuba, K., & Marlicz, W. (2026). Microbiome-directed therapies in oncology: from animal models to clinical implementation. Best Practice & Research Clinical Gastroenterology, 83, 102148. https://doi.org/10.1016/j.bpg.2026.102148

Vancouver

Skonieczna-Żydecka K, Marlicz M, Kaczmarczyk M, Łoniewski I, Boluk P, Ekstedt-Biskot N, et al. Microbiome-directed therapies in oncology: from animal models to clinical implementation. Best Practice & Research Clinical Gastroenterology. 2026;83:102148. doi:10.1016/j.bpg.2026.102148

BibTeX
@article{Skoniecznaydecka2026,
  author = {Skonieczna-Żydecka, Karolina and Marlicz, Maria and Kaczmarczyk, Mariusz and Łoniewski, Igor and Boluk, Patrycja and Ekstedt-Biskot, Natalia and Kutrzuba, Krzysztof and Marlicz, Wojciech},
  title = {Microbiome-directed therapies in oncology: from animal models to clinical implementation},
  journal = {Best Practice & Research Clinical Gastroenterology},
  year = {2026},
  volume = {83},
  pages = {102148},
  doi = {10.1016/j.bpg.2026.102148}
}
Kostenlos starten →